Slide1

Theranos Lab Practices Pose Risk to Patient Health, Regulators Say

Federal inspectors found “deficient practices” at a Theranos Inc. laboratory that “pose immediate jeopardy to patient health and safety,” according a letter released last week, reports the Wall Street Journal. The Centers for Medicare and Medicaid Services said an inspection completed in November at the company’s lab in Newark, Calif., uncovered five major infractions that violate the federal law governing clinical labs. Theranos, valued at $9 billion, has been under fire since an October Wall Street Journal report revealed that the company’s inventions were only used on a small number of tests sold to patients. A follow-up report said that Theranos had actively hidden its proprietary technology from lab inspectors during previous inspections.